CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress
Reuters
Oct 06
CARsgen <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress
CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology $(ASH)$ in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.